These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32222087)

  • 41. Distinct Clinicopathologic Features and Possible Pathogenesis of Localized ALK-positive Histiocytosis of the Breast.
    Osako T; Kurisaki-Arakawa A; Dobashi A; Togashi Y; Baba S; Shiozawa S; Ishigame H; Ishige H; Ohno S; Ishikawa Y; Takeuchi K
    Am J Surg Pathol; 2022 Mar; 46(3):344-352. PubMed ID: 34482333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features.
    Chiang S; Samore W; Zhang L; Sung YS; Turashvili G; Murali R; Soslow RA; Hensley ML; Swanson D; Dickson BC; Stewart CJR; Oliva E; Antonescu CR
    Am J Surg Pathol; 2019 Jun; 43(6):810-818. PubMed ID: 30829727
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expanding the Spectrum of Adult NTRK3-Rearranged Spindle Cell Neoplasms: A Recurrent NTRK3-SQSTM1 Fusion Spindle Cell Tumor With Deceptively Bland Morphology.
    Punjabi LS; Sittampalam K
    Am J Clin Pathol; 2022 Apr; 157(4):485-493. PubMed ID: 34661642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors.
    Agaram NP; Zhang L; Sung YS; Chen CL; Chung CT; Antonescu CR; Fletcher CD
    Am J Surg Pathol; 2016 Oct; 40(10):1407-16. PubMed ID: 27259011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutaneous Non-Neural Granular Cell Tumors Harbor Recurrent ALK Gene Fusions.
    Cohen JN; Yeh I; Jordan RC; Wolsky RJ; Horvai AE; McCalmont TH; LeBoit PE
    Am J Surg Pathol; 2018 Sep; 42(9):1133-1142. PubMed ID: 30001233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ALK-Rearranged Epithelioid and Spindle Cell Neoplasm of the Sinonasal Tract.
    Zhu P; Wang J
    Int J Surg Pathol; 2024 Oct; 32(7):1332-1338. PubMed ID: 38303518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of angiomyofibroblastoma and aggressive angiomyxoma in both sexes: four cases composed of bimodal CD34 and factor XIIIa positive dendritic cell subsets.
    Silverman JS; Albukerk J; Tamsen A
    Pathol Res Pract; 1997; 193(10):673-82. PubMed ID: 9505259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases.
    Dickson BC; Swanson D; Charames GS; Fletcher CD; Hornick JL
    Mod Pathol; 2018 May; 31(5):753-762. PubMed ID: 29327718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ALK Gene Fusions in Epithelioid Fibrous Histiocytoma: A Study of 14 Cases, With New Histopathological Findings.
    Kazakov DV; Kyrpychova L; Martinek P; Grossmann P; Steiner P; Vanecek T; Pavlovsky M; Bencik V; Michal M; Michal M
    Am J Dermatopathol; 2018 Nov; 40(11):805-814. PubMed ID: 29329131
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology.
    Kashima J; Yoshida M; Jimbo K; Izutsu K; Ushiku T; Yonemori K; Yoshida A
    Am J Surg Pathol; 2021 Mar; 45(3):347-355. PubMed ID: 32826530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
    Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
    PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 54. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
    Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
    J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular investigation of ALK-rearranged epithelioid fibrous histiocytomas identifies CLTC as a novel fusion partner and evidence of fusion-independent transcription activation.
    Georgantzoglou N; Green D; Winnick KN; Sumegi J; Charville GW; Bridge JA; Linos K
    Genes Chromosomes Cancer; 2022 Aug; 61(8):471-480. PubMed ID: 35289445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. S100 and CD34 Expressing Mesenchymal Neoplasm With Rare PLEKHH2::ALK Fusion and Response to ALK Inhibition.
    Coppock JD; Schneider MA; Surrey LF; Karakousis GC; Maki RG; Cooper K
    Am J Surg Pathol; 2022 Sep; 46(9):1309-1313. PubMed ID: 35288525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
    Subbiah V; Westin SN; Wang K; Araujo D; Wang WL; Miller VA; Ross JS; Stephens PJ; Palmer GA; Ali SM
    J Hematol Oncol; 2014 Jan; 7():8. PubMed ID: 24422672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myoepithelioma-like Hyalinizing Epithelioid Tumors of the Hand With Novel OGT-FOXO3 Fusions.
    Lee JC; Chou HC; Wang CH; Chu PY; Hsieh TH; Liu ML; Hsieh SM; Liu YR; Kao YC
    Am J Surg Pathol; 2020 Mar; 44(3):387-395. PubMed ID: 31567281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.
    Davis LE; Nusser KD; Przybyl J; Pittsenbarger J; Hofmann NE; Varma S; Vennam S; Debiec-Rychter M; van de Rijn M; Davare MA
    Mol Cancer Res; 2019 Mar; 17(3):676-685. PubMed ID: 30518629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.